Completed the second round of fundraising, raising gross proceeds of approximately RMB700 million in aggregate from strategic investors including CMS Venture, Hangzhou Gongshu, YD Capital, Hangzhou Taikun, Hangzhou Investment and TG Sino-Dragon.

Completed the acquisition of Kyowa Kirin China. As part of the acquisition, we obtained the exclusive rights to develop, manufacture and commercialize five originator drugs and a manufacturing facility in Shanghai covering approximately 43,000 m². This marked a pivotal milestone in our strategic development and expansion.

Completed the acquisition of DDAG, a company incorporated in Switzerland and principally engaged in the production and sales of dietary supplements and drugs.

Completed our first round of fundraising, raising gross proceeds of approximately RMB520 million in aggregate from strategic investors including LYFE Mount, LYFE Kings and Kaitai Capital.

Entered into a strategic partnership with Kyowa Kirin, becoming the exclusive CSO for the originator antihypertensive drug Coniel® in mainland China.

Our Company was incorporated in the BVI on March 13, 2015.
Entered into a strategic partnership with Roche Pharma (Schweiz) AG, becoming the exclusive CSO for the anti-influenza drug Tamiflu® in mainland China.

Our Group was established through the acquisition of the entire equity interest in Zhejiang Medical and commenced operations.